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Abstract
Metastatic brain tumors (MBTs) are the most common intracranial tumor and 
occur in up to 40% of patients with certain cancer diagnoses. The most common 
and frequent primary locations are cancers originating from the lung, breast, kid-
ney, gastrointestinal tract or skin, and also may arising from any part of the body. 
Treatment for brain metastasis management includes surgery, whole brain radio-
therapy (WBRT), stereotactic radiosurgery (SRS), and chemotherapy. Standard 
treatment for MBTs includes surgery and SRS which offer the best outcomes, while 
the WBRT is still an important treatment option for patients who cannot tolerate 
surgery and SRS or patients with multiple brain metastases. Newer approaches such 
as immunotherapy and molecularly targeted therapy (e.g., small molecules and 
monoclonal antibodies) are currently being evaluated for the treatment of MBTs. 
In this chapter, we will review current available treatments for MBTs and discuss 
treatments that are undergoing active investigation.
Keywords: brain metastasis, chemotherapy, radiotherapy, targeted-therapy, 
neuroimaging
1. Introduction: epidemiology and pathophysiology
Metastatic brain tumors (MBTs) are the most common central nervous system 
tumors in the United States [1, 2]. Patients are living longer with cancer with the 
advent of imaging modalities leading to earlier detection and improved systemic 
therapies. As a result, the probability of patients developing brain metastases (BM) 
over time has increased [2]. A number of studies support the expected trend of ris-
ing MBT incidence. A cohort study in Sweden found the incidence for brain metas-
tases doubled from 1987 to 2006 [3]. Another study from the Swedish National 
Cancer Registry reported that patients diagnosed with breast cancer from 2004 to 
2006 had a 44% increase in risk in brain metastasis as compared to patients in 1998 
and 2000 [4]. A forecast for greater frequency of metastatic brain cancer (MBC) 
emphasizes the need for continued innovation in MBT treatment.
Roughly 200,000 patients are newly diagnosed with MBC annually in the United 
States [5, 6]. The incidence rate for primary central nervous tumors was estimated at 
6.4 per 100,000, while the incidence for metastatic brain tumors has been estimated 
between 8.3 and 11.3 per 100,000 [2, 7]. More recent studies suggest that MBTs 
may occur as much as 10 times more frequently than primary tumors [2, 8, 9]. For 
cancer patients, an estimated 8.5–9.6% will be diagnosed with brain metastasis [2]. 
In adults, the most common sources of brain metastases are lung, breast, melanoma, 
renal and colorectal cancer [10–13]. Another study of patients in Detroit from 1973 
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to 2001 found the incidence for brain metastases for melanoma (6.9%) and renal car-
cinoma (6.5%) superseded breast cancer (5.1%) as the second and third most com-
mon sources [5]. A 2002 study examined patients from 1986 to 1995 and found renal 
carcinoma was the second most common MBC followed by melanoma and breast 
cancer [14]. In contrast, MBC in children has the lowest incidence and has previ-
ously estimated at 1.5 per 100,000 between the ages of 0 and 14 years [15]. A study 
following children diagnosed with cancer at MD Anderson Cancer Center found 
1.4% of individuals had a BM, which most commonly originated from sarcomas and 
melanomas [16]. Previous studies reported incidence as high as 4 and 4.9% among 
children diagnosed with solid tumors [17, 18]. For adults, melanoma, testicular and 
renal carcinomas have the greatest tendency to metastasize to the brain, but their 
relative scarcity translates to lower frequencies compared to other types of metastatic 
brain cancers [13] Whereas metastases in children most frequently emanated from 
neuroblastoma, sarcomas, and germ cell tumors [18–20].
Barnholtz-Sloan et al. reported that race, gender and age impact the incidence 
of brain metastasis. Shifts in these demographic features of MBC can be explained 
by the rising incidence of lung cancer among women compared to men [5, 21]. 
Investigation by Barnholtz-Sloan found that men had higher incidence percentage 
(IP%) of BM for each type of systemic cancer with the exception of breast and lung 
cancers. In patients with lung cancer, the cumulative incidence for BM in women 
was 21.8 and 18.9% for men [5]. There is a higher cumulative incidence of BMs in 
African Americans as compared to Caucasians for lung, melanoma, and breast can-
cers [5]. Renal cancers displayed a higher IP% among Caucasian patients compared 
to African American patients. Lastly, the IP% for colorectal cancer was similar 
between the two populations [5]. The frequency of BM increases with age for most 
cancer types. Primary cancers presenting with BM increases proportionally with 
age with a peak around 60 years old [22]. A 1996 study estimated incidence rates for 
MBTs by age and found the highest incidence was in the age bracket of 65–74 years 
at 53.7 per 100,000 [15].
1.1 Clinical presentation
MBTs might present with a number of different signs and symptoms. The most 
common clinical sign is headache, which occurs in as many as 50% of cases [23]. 
Headaches that are ≤10 weeks in duration have been suggested to be more predic-
tive of BM [24]. These headaches usually can be generalized or localized. They can 
persist for hours and reoccur at various intervals. Tension headaches, migraines and 
even cluster type headaches are not uncommon. Lateralization of the headaches to 
the ipsilateral side only happened in the minority of cases [25]. The headaches have 
been suggested to be due to increase intracranial pressure due to mass effect and a 
resulting hydrocephalus. An even smaller number of patients (~20%) have a result-
ing papilledema due to increase intracranial pressure. Another common presenting 
symptom is nausea and vomiting. This has been suggested to occur in as many as 
54% of cases to as few as 12% of cases [26, 27].
Focal neurological deficits are a common clinical manifestation of MBTs. They 
occur in approximately 40% of cases [28]. The deficits that patients suffer depends 
on a number of factors including number of BMs, areas of the brain affected, and 
more tumor specific factors such as growth, associated swelling or recent hemor-
rhage. These deficits can progress as the tumor increases in size. These symptoms 
can present acutely in a stroke-like manner due to hemorrhage or as a slow ominous 
progression. Weakness has been the primary presenting complaint in between 20 
and 40% of BMs. Sensory deficits have been reported to be slightly less common 
than weakness.
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Other frequently encountered symptoms included altered mental status, 
seizures, ataxia, and dysphagia. The actual rates of occurrence are not clear. These 
variations are largely predicated on the fact that MBTs unpredictably seed the 
central nervous system. Most frequently BMs seed the frontal lobe (32%). The 
parietal (18%), occipital (13%), and temporal (12%) lobes each make up a signifi-
cant portion. Cerebellar metastases make up approximately 18% of BM. The least 
common area is the brainstem [26, 29, 30]. Studies have suggested that the sites of 
BMs vary based on the primary site of origin and cerebral blood flow. There are data 
that suggest that the differences in surface characteristics make specifics sites more 
conducive to invasion by circulating cancer cells. The exact mechanisms or charac-
teristics have not been elicited [31].
1.2 Genomics
Metastatic tumors may have very different rates of occurrence and different 
responses to treatment. There are a number of studies that suggest that these can 
be explained by genetic and/or epigenetic differences. Research on BM models has 
shown idiosyncratic expressions of genes that mediate metastasis [32, 33]. Several 
chromosomal translocations are associated with the development of brain metastases. 
Lee et al. identified that regions 5q53, 10q23, and 17q23-24 were correlated with devel-
opment of BM within 3 months of primary tumor diagnosis [34]. Specific genes have 
also been associated with development of BM in lung cancer such as PLGF, VEGFR1, 
c-MET, and CXCR4 [35–37]. Other genes suggest a greater risk for brain relapse 
[38–42]. Metastatic pathophysiology is not limited to protein-coding regions, since 
non-coding RNA regions are associated with many cancer types [43]. Studies docu-
menting unique mutations in MBTs compared to the source tumor indicate lesions 
evolve in character and underscore the need for genomic evaluation for best-fit 
therapies [44]. Although the molecular mechanisms leading to early brain metastasis 
are poorly understood, these insights provide potential targets for therapy.
1.3 Microenvironment
A growing focus among researchers is understanding the dynamic interactions 
of cancer cells with astrocytes that may provide several novel therapeutic options. 
Following extravasation, individual cancer cells are surrounded by reactive astro-
cytes [45, 46]. Astrocytes serve as the first line of protection in the central nervous 
system (CNS) [45, 47, 48]. With regard to brain metastasis (BM), astrocytes reduce 
the number of potential metastatic cells by activating plasmin [45]. Adaptive cancer 
cells can evade these defense systems by expressing serpins [45]. Serpins represent a 
target for future therapies.
Neoplastic cells surviving this phase usually seed in the perivascular niche [49, 50],  
adjacent to neural stem cells and nearby nutrient and oxygen supplies [51–53]. 
Proliferation in perivascular niches establishes micrometastases where only a fraction 
of sites reach detectable volumes [54]. Recent research suggests the natural selection of 
micrometastases is regulated by reactive astrocytes in the microenvironment [55, 56].  
Astrocytic-neoplastic interactions depend upon the presence of protocadherin 7 
(PCDH7) which mediates contact between the cell groups [56]. Following interaction, 
gap junctions form and cell-cell communication occurs that increase cancer cell growth 
and resistance to chemotherapeutic apoptosis [57]. Born out of the pro-metastatic 
astrocytes research, silibinin represents a targeted therapy attacking the microenviron-
ment with promising results [58]. Meclofenamate and tonabersat are another promis-
ing set of medications that target carcinoma-astrocyte gap junctions that suppressed 
brain metastasis in mice models [56].
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2. Metastatic brain tumor diagnosis
Magnetic resonance imaging (MRI) is the current gold standard for brain mass 
evaluation. MRI provides a wide array of benefits including lesion detection and 
characterization as well guiding treatment by establishing differential diagnoses, 
guiding invasive procedures, and monitoring patients for changes over time. Within 
the past decade we have witnessed imaging transition from indirect diagnosis of 
lesions using cerebral angiography to precise lesion diagnosis by implementing 
multi-planar CT and MRI. Modern tumor imaging can be categorized as anatomic, 
metabolic, and functional (physiological) in nature. This section reviews conven-
tional and advanced imaging techniques provided by CT, MRI, PET, and biomark-
ers as it relates to the management of metastatic brain cancer.
2.1 Computer tomography
Computed tomography images are obtained by transmitting precisely col-
limated beams of radiation through specimens at multiple angles. Detectors 
opposite the radiation source record absorbed and scattering of beams whereby 
computer algorithms derive attenuation at each location. Currently, multislice 
CT scanners (MSCT) implement a multilayered matrix system of detectors to 
generate registration simultaneously for several helical trajectories [59]. The chief 
advantage of MSCT is higher resolution and faster scan times. Metastases appear 
as isodense lesions or lower density relative to the density of normal brain matter 
in native CT scans. Tumor boundaries can be distinguished adjacent to edematous 
regions. Nonenhanced CT is capable of detecting neurosurgical emergencies such as 
hydrocephalus, hemorrhage, and mass effect. In cases where patients have implants 
that are not compatible with MRI, we still rely heavily on CT for diagnosis and to 
evaluate response to treatment. Another advantage of CT is its ability to detect the 
extent of bony destruction from calvarial metastases [60]. Sensitivity and ionizing-
radiation exposure are the two main limitations when imaging for tumors with 
CT. Visibility of metastases can be enhanced with contrast-based injections typi-
cally with iodine-based injections [61].
Three-dimensional (3D) imaging technology has improved the standards of neu-
rosurgical diagnostics and planning in general [62, 63]. 3D renderings convey greater 
information (e.g., the scope of bony involvement and destruction) and improves 
localization of abnormal lesions in relation to surrounding tissues. Combining 3D 
technology with CT angiography (CTA) helps elucidate tumor blood supply and 
their orientation with cerebral arteries. Visualizing vasculature information permits 
better planning for surgical access and the extent of tumor resection. CTA provides 
higher spatial resolution than MR angiography (MRA), but poorer contrast between 
arteries and surrounding tissues. One of the more useful CT technological advances 
in the treatment of brain tumors is perfusion CT. Perfusion CT (PCT) administers 
an intravenous bolus of contrast agent to evaluate changes in density characteristics 
of tissue. Quantitative estimates of hemodynamic perfusion cerebral blood volume 
(CBV), cerebral blood flow (CBF), mean transit time (MTT), microvascular perme-
ability (PS) can be acquired for monitoring the effectiveness of cancer treatment. 
This technique opens up the possibility for measuring the hemodynamics in brain 
tissue, tumors, and proximate regions. Perfusion methods estimate and quantify 
blood flow feeding brain regions through specialized workstations calculating 
CBF, CBV, MTT, and PS parameters for each voxel [64, 65] Initially, CT perfusion 
was utilized to evaluate the extent of ischemic brain damage by visualizing brain 
hypoperfusion within minutes of an ischemic attack [66, 67]. More recently, PCT 
has been implemented for brain tumor diagnosis and differentiation from adjacent 
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lesions based on hemodynamic characteristics [68, 69]. Visual perfusion analysis 
reconstructs parametric color maps that are proportional to the selected perfusion 
parameter. Maps codify the quantitative data into a visual system, which allows 
medical specialists to examine the vasculature supplying structures of interest 
[70]. It also allows greater appreciation of solid components and distinguishing the 
regions of viable neoplastic tissue. Parametric maps for CBF and MTT have been 
used to generate mean values for different metastatic tumor types, which may serve 
to predict the sources of tumors. A comparative assessment of perfusion parameters 
performed on varying lesion sizes found CBF values were higher than in smaller 
lesions. However, MTT values were not affected significantly with regard to lesion 
size. Presently, CTP is implemented for primary diagnosis of MBTs and assessing 
post-radiation changes. Changes in the perfusion parameters proved more effective 
for monitoring radiation therapy at earlier stages (2 months post-treatment) when 
compared to CT and MRI methods [71]. Lastly, positron emission imaging hybrid-
ized with CT image data (PET-CT) can serve to localize brain abnormalities with 
useful anatomical landmarks while correcting photon attenuation.
2.2 Magnetic resonance imaging (MRI)
MR imaging utilizes electromagnetic waves in radiofrequency ranges to generate 
incident energy and contrast between tissues. Advantages of MRI compared with 
CT include superior contrast in soft tissues, greater selection of contrasts between 
tissues, versatility of advanced imaging techniques, and lack of ionizing radiation 
[72]. Pulse sequences are different patterns of incident radiofrequency waves that 
generate multiple types of contrast between tissues. After a radiofrequency wave 
emitted by the scanner perturbs nuclei of the body, the body transmits a signal to 
MRI receivers. The returning waveform varies based on the rate of relaxation of the 
excited nuclei towards its initial state. Two types of relaxation are measured, i.e., 
longitudinal and transverse. T1 sequence is the time it takes longitudinal magneti-
zation to return to 63% of its equilibrium value after excitation. While, T2 sequence 
is the same percent value for transverse magnetization. Each sequence has specific 
functions with particular advantages and disadvantages relative to others.
Typically, tumors have greater water content than brain parenchyma and thus 
exhibit hypoattenuation on T1-weighted images relative to parenchyma. This pattern is 
regularly altered with the presence of necrosis, fat, proteinaceous fluid, hemorrhage, 
and calcifications. MBTs, in particular, are roughly spherical, highly vascularized 
and tend to hemorrhage more than primary brain tumors. The effects of hemorrhage 
oftentimes obscure tumors and hematomas and require follow-up imaging, imaging 
with contrast or perfusion-based imaging to reveal an underlying image. Metastases 
develop in parenchyma and wide range of nonparenchymal regions including cal-
varium, diploic space, meninges, choroid plexus, and pituitary gland. Typically, 
contrast-enhanced MRI is the preferred imaging modality for evaluating metastases in 
these regions for its superior contrast, resolution, and multitude of sequences [73].
MR has higher sensitivity for recognizing small metastases compared to CT 
and CT/PET [74, 75]. Knowledge of the size, location, and number of metastases 
are essential in treating patients with MBs. The ability to detect very small tumors 
is essential in treatment. Multiple gadolinium-based contrast agents (GBCA) are 
available to enhance the sensitivity of MRI scans. These agents vary in biophysical 
properties but generally increase T1 relaxivity resulting in greater signal-to-noise 
ratios [76, 77]. Increasing GBCA leads to increased sensitivity, particularly for 
lesions smaller than 5 mm, but at the expense of increasing false-positive results 
[78]. In the same vein, stronger magnets (1.5–3.0 T) increase MRI field strengths 
and improves metastatic detection. Theoretical predictions suggest signal-to-noise 
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ratios (SNR) should improve linearly as field strength increases [79]. Altering these 
two variables has profoundly improved sensitivity for detection of suspected meta-
static lesions [80, 81]. The emergence of 7 T MRI machines may allow for better 
lesion detection while reducing the contrast dose and scan time [82]. In light of the 
association between GBCA and nephrogenic fibrosis, higher doses may be avoided 
without compromising scan quality. Magnets have been manufactured for 8 and 
9.4 T systems are currently being used on humans [83]. We expect image quality 
and tumor elucidation to continue to improve into the near future. Another option 
for enhancing detection is to increase time delay between contrast administration 
and T1 acquisition [84]. The development of machine learning and automated 
detection of brain lesions with human interpretation could generate greater sensi-
tivity and accuracy of lesion characterization [85, 86].
The hallmark of malignancy is uncontrolled cell proliferation and an increase 
in blood supply once the tumor reaches 2–4 mm3 [87]. Tumor growth leads to focal 
hypoxia and hypoglycemia which stimulates angiogenesis. Tumor-derived blood 
vessels differ from normal brain vessels in vascular consistency, fragility, perme-
ability, trajectory underlie the differences observed in hemodynamic parameters 
measured in MRI perfusion [88–90]. MRI perfusion technique administers a bolus 
of contrast agent and calculates the intensity of the MR signal during its transit 
[91–93]. CBF, CBV, and MTT maps assess tumor vascularity similar to PCT, but 
perfusion MRI avoids several pitfalls, e.g., radiation exposure and iodine-based 
contrast agents. MR perfusion has several common techniques including dynamic 
susceptibility contrast (DSC), arterial spin labeling (ASL), and dynamic contrast-
enhanced (DCE) which have different tradeoffs. Ktrans is a DCE derived perfusion-
based metric that describes leakiness of blood vessels [94]. ASL can be acquired 
without GBCA by labeling blood water protons to generate an endogenous tracer 
[95]. MRI perfusion also maintains its superior anatomical characterization of 
tumors along with hemodynamic measurements [96, 97]. While perfusion MRI has 
existed for over 20 years, it has not been used as much as other techniques and has 
not become standard of care for brain tumor patients [98, 99]. Reasons for under-
utilization include an unclear reimbursement scheme, lack of approved GBCA for 
perfusion MRI, insufficient methodological standardization, and limited evidence 
supporting a significant advantage for patients than current practices [99]. Despite 
these limitations, perfusion MRI is an intriguing candidate for determining tumor 
grade, prognosis and therapeutic efficacy.
2.3 Metabolic imaging: PET
Positron emission tomography (PET) is an imaging technique that depicts the 
metabolism of brain metastases and other brain lesions [100]. A wide range of 
PET tracers are labeled with a positron-emitting radionuclide to promote decay by 
positron emission. Collisions with nearby electrons produces two gamma-rays with 
a fixed energy separated by 180°. Detectors absorb the photon energy and reemit 
the energy as visible light. Visible light is converted into electrical current, which is 
proportional to the incident photon energy and reconstructed into a 3D image [101–
103]. Common positrons employed with tracers consist of 18F (110-minute half-life) 
and 11C (20-minute half-life). While the most common tracer is FDG, a glucose 
analog taken up by insulin-dependent GLUT 1 transporters. Phosphorylation of 
the tracer inside the cell prevents further metabolism resulting in greater uptake in 
cells that are metabolically active. Image registration is exceedingly important to 
accurately correlate PET metabolic findings with MRI abnormalities.
There are several limitations for FDG tracers within the brain. One important 
problem is the high background activity present in the cortex and basal ganglia as 
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a result of these tissues elevated glucose consumption. High background activity 
sizeably degrades the SNR and reduces image sensitivity, which is critical for distin-
guishing small lesions from cortical regions [104]. Resolution is another hindrance 
(5 mm compared to sub 2 mm for MRI) stemming from multiple technical factors. 
As a consequence, both sensitivity and specificity for FDG PET are reduced for the 
detection of brain metastases when compared to MRI [75, 105, 106]. Therefore, FDG 
uptake is not specific for solely brain tumors, but may also indicate nontumorous 
lesions such as inflammatory lesions, focal epilepsy, and recent ischemic infarcts.
Despite the aforementioned limitations for diagnosing lesions, PET is particu-
larly adept at differentiating between recurrent or residual tumor and necrotic 
tissue post-radiation therapy [107]. One study found that sensitivity of FDG-PET 
for detecting recurrent tumors versus radiation-induced necrosis was 75% and the 
specificity was 81% [108]. However, significant variation has been observed for 
low-grade, high-grade tumors, inflammatory and other brain lesions [109]. Another 
utility of PET is discerning responders from nonresponders in its earliest stages 
during chemotherapy treatment. Identification of nonresponders has practical 
implications in avoiding essential bone marrow reserves, patient quality of life, and 
unnecessary expenses on ineffective treatment [110].
Constraints posed by FDG tracer has researchers focused on developing alterna-
tive tracers to capture greater metabolic information and produce favorable imaging 
outcomes. Tracers reflecting amino acid metabolism help to characterize metastatic 
brain tumors. Amino-acid tracers take advantage of the L-amino acid transporter 
type 1 system to avoid the inefficient process of blood-brain barrier (BBB) break-
down for uptake. Alternative uptake for amino acid tracers greatly reduces brain 
background activity and correlates with a variety of malignant activities, e.g., cell 
proliferation and angiogenesis. Amino acid tracers appear to perform better than 
FDG tracer in differentiating postradiation changes from recurrent tumors. Even in 
brain lesions without increased uptake for FDG-PET, sensitivity and specificity for 
tumors (89 and 100%) were obtained [111].
2.4 Proton magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is a noninvasive MRI technique that 
produces metabolic spectra rather than producing anatomic images. Several nuclei 
(proton, carbon, sodium, fluorine) can be used but proton is the most common 
because of its high sensitivity. MRS can be used to measure the metabolite concen-
trations or the chemical composition of tissues. Commonly measured metabolites 
include N-acetyl aspartate (NAA) and choline (Cho) that are markers for neuronal 
integrity and membrane turnover in gliomas. Lactate, lipids, amino acids, and 
myoinositol can also be detected by MRS [112, 113]. MRS imaging of peri-enhancing 
brain regions may be useful for distinguishing solitary metastases from primary brain 
tumors. Gliomas often show elevated Cho in surrounding tissue, whereas MBTs are 
generally encapsulated and do not exhibit elevated Cho signals [114, 115]. Elevated 
Cho and lipid signals on MRSI make glioblastomas more likely than MBC [116]. MRSI 
may also have a role in evaluating prognosis based upon metabolite ratios [117–119]. 
However, MR spectroscopy was not adept at differentiating metastatic brain tumors 
of disparate etiologies. For that reason, its utility in MBT diagnostics is unproven [59].
2.5 Functional imaging
A unique feature of MRI is the ability to visualize thermal or Brownian motion 
of water molecules in the brain tissues. Diffusion properties of water in an iso-
tropic medium is represented by Fick’s law relating molecular flow vectors to 
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concentration gradient [120]. Water molecules in solutions above absolute zero 
exhibit Brownian motion, which in pure water behaves randomly and isotropically. 
The higher the diffusion coefficient value, the greater the distance molecules can 
move within the same time period. Apparent diffusion coefficient (ADC) acts as 
a surrogate for this motion and can be calculated by MRI techniques. B values are 
parameters of DWI pulse sequence and represent the diffusion weighting. DWI 
acquisition with a minimum of two distinct b values enables derivation of dif-
fusivity for each individual voxel. Multiple images with varying b values generate 
ADC maps. Molecular water movement occurs within individual cells (restricted 
diffusion) and extracellular spaces amongst structures that constrain the motion 
of molecules (free and hindered diffusion). Generally, the magnitude of diffusion 
coefficient is dependent on microstructural organization and its respective chemi-
cal composition. Abnormal areas of reduced diffusion appear bright on DWI. The 
first diffusion-weighted image (DWI) was procured in 1985, but DWI did not reach 
clinical practice until the third generation of MR scanners emerged [121, 122].
On diffusion-weighted MR imaging, MBTs are characterized by heterogeneous 
changes on DWI and ADC maps. Homogenous MRI signals on DWI usually 
originated from solid lesions. A variety of biophysical conditions of tissue can 
result in reduction of diffusion. For instance, edema and increased cellularity can 
inhibit the motion of water molecules. DWI is considered the standard imaging 
technique for early diagnosis of cerebral ischemia, as it visualizes impaired diffu-
sion following cytotoxic edema and microstructural damage to cells. In addition to 
this clinical application, DWI is highly sensitive to cerebral abscesses, epidermoid 
cysts, traumatic shearing injuries, encephalitis, and postoperative brain injury. One 
major drawback to DWI is the sensitivity to lesions containing high concentrations 
of magnetic materials, e.g., blood products, calcium, metal, bone or air. This is 
particularly true for postoperative DWI imaging.
2.6 Diffusion tensor imaging
Within certain brain tissues, barriers restricting water diffusion are isotropi-
cally distributed meaning water diffuses in all directions. At other sites in the 
brain, barriers will be distributed anisotropically leading to directional diffusion 
perpendicular to the barriers. In white matter, diffusion runs parallel to axonal 
projections and myelin fibers and restricted perpendicularly by biological mem-
branes. Diffusion tensor imaging applies diffusion gradients in three orthogonal 
directions. When the three directions are compared, important differences 
become visible. The corpus callosum exhibits these differences with the greatest 
intensity. When diffusion gradients are applied in the z direction, diffusion is 
greatly restricted and has low signal intensity. When the gradient is applied in the 
x direction, diffusion is unrestricted in the right-to-left orientation and parallel to 
the corpus callosum fibers. This region of the brain displays anisotropy with the 
greatest intensity. Tensor models help quantify diffusion anisotropy by measur-
ing ADC in three perpendicular directions x, y, and z and all combinations of 
the selected directions. Diagonal elements are transformed to coincide with the 
principle axis of diffusion for each voxel. New diagonal elements correspond to 
three eigenvectors and three eigenvalues codifying the main directions of diffusion 
and associated diffusivities (radial, axial, median). Fractional anisotropy (FA) 
measures the mean anisotropic diffusion. Color-coded maps can then be developed 
corresponding to directionality of water movement along axons.
DTI-tractography is a post-processing method for selecting white matter 
pathways in the brain. Fiber bundles in the brain correspond to the color maps. 
Diffusion tensor MRI is the means for evaluating the brain with attention to the 
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anatomic microstructure or brain white matter. These white matter maps can then 
be used to infer functional pathways. This knowledge allows neurosurgeons to 
plan surgical resections with a better margin of safety. Before the onset of modern 
brain mapping, complications rates for brain tumor resections were as high as 26% 
[123–126]. DTI and presurgical brain mapping have made a tremendous impact on 
surgical risk-benefit analysis and outcomes following surgery [127]. Tractography 
provides the qualitative information for assessing nerve bundle status, whether 
there is mass effect, tumor infiltration, edema, or functional reorganization [128]. 
Mass effect often leads to deviation in nerve tracts. Infiltration refers to any sec-
tion of the tract with lower anisotropy but preserved morphology. Degeneration 
of tracts can be visualized with reduced fiber size or lower anisotropic values. 
Finally, fibers may appear interrupted or discontinuous indicating organizational 
alteration lesions. Appreciation of these features by surgeons allows for preopera-
tive planning for maximal resection, targeting specific regions for biopsy, and 
avoiding functional tissue. DTI is a promising imaging technique for examining 
microscopic differences in tumors. In combination with intraoperative localization 
techniques, neurosurgeons can tailor presurgical mapping data to reduce opera-
tion times by testing language and motor functions while dissecting along tumor 
borders. Electrical stimulation is one method implemented for testing the white 
matter function [129, 130]. Transient speech or language deficit during dissection 
means imminent white matter injury is within millimeters beyond the dissection 
plane. Importation of DTI mapping data into neuronavigation systems allow real-
time interaction with spatial relationships between lesions and functional nerve 
pathways.
2.7 Advanced diffusion imaging
High angular diffusion imaging (HARDI) method detects diffusion greater 
directions than DTI. HARDI implements 55 to over 100 gradient directions as 
compared to the standard 6 gradient directions in DTI [130]. The HARDI model 
estimates fiber orientations (orientation distribution function) that minimizes 
scan acquisition time compared to other methods (diffusion spectrum imaging). 
By changing from an ellipsoid model to orientation distribution function, HARDI 
appreciates multiple fibers in a single voxel. Scan acquisition time for DTI is roughly 
3–10 minutes, whereas HARDI requires a minimum of 12 minutes. HARDI scan 
times are more reasonable for research and clinical use as opposed to other novel 
techniques [130].
By propagating fiber trajectories in multiple alternative directions, HARDI is 
more sensitive in picking up fibers displaced by brain lesions. White matter critical 
for speech, language, and motor functions better delineated by HARDI in cases 
where lesion-induced deviation or interruption may occur. Corticospinal tracts 
(CST) near the centrum semiovale run against crossing white matter tracts from the 
corpus callosum and superior longitudinal fasciculus [131]. Identifying motor fibers 
represented by CST is critical for presurgical brain mapping in tumor resection 
cases.
Neurite orientation dispersion and density imaging (NODDI) is a recent diffu-
sion MRI technique detecting microstructural features of brain tissue with higher 
resolution than DTI [132, 133]. NODDI maps both gray and white matter micro-
structure. Detection of diffusion for both dendrites and axons constitutes the term 
neurite. Neurite density (intracellular volume fraction) and orientation dispersion 
are calculated using 17 b values and 153 gradient directions, making it tedious for 
clinical translation [134]. Quantifying neurite morphology in terms of density 
and orientation provides alternative information for the structural basis of brain 
Brain and Spinal Tumors - Primary and Secondary
10
disorders. Branching complexity can be computed in terms of dendritic density. 
Areas with less complex dendritic structures tend to engage in early information 
processing, while regions with greater complexity participate in the end stages of 
information processing [135]. Changes in neurite morphology is associated with 
development as humans age [136], numerous neurological disorders including 
multiple sclerosis [137], amyotrophic lateral sclerosis [138, 139], and Alzheimer’s 
disease [140].
Prior to the advent of NODDI, changes in the brain microstructure from brain 
disorders were studied using scarce postmortem tissue samples. There is growing 
evidence that neurite morphology from NODDI methods is comparable to indepen-
dent measures derived from histology [141]. NODDI provides a promising tool for 
differentiating glioblastomas from solitary brain metastases and assessing tumor 
malignancy grades [142–144].
3. Metastatic brain tumor therapeutics
3.1 Surgery
Despite advances in other technologies, surgical resection of BMs remains 
a mainstay of treatment. Surgical resection provides a number of immediate 
benefits to patients including symptomatic relief from BMs through resolution 
of mass effect and reducing edema [145]. Often this is for emergent situations in 
which complications, like increased intracranial pressure, become life threaten-
ing. Surgical resection of the tumor can also be a non-pharmacological solution to 
seizures. The epileptic medications can have significant interactions with chemo-
therapy due to inhibition of the cytochrome p450. Another valuable product of 
surgical resection is histological evaluation of the tumor. This gives pathologist a 
change to determine the source of metastatic tumors in the event of undiagnosed 
primary disease, and also the opportunity to evaluate the genetic variations to help 
guide further clinical decision making.
Aggressive surgical resection of BMs of solitary tumors has gained greater popu-
larity in the last few decades. This type of management gained more traction in the 
90s and early 2000s when studies began to show benefits for surgical resection over 
radiation therapies. Studies demonstrated a reduction in local recurrence, increase 
life expectancy, and improved quality of life [146–148]. The difficulties in assessing 
the indications for surgical resection over other treatment modalities have led to the 
development of nonograms like recursive partitioning analysis (RPA) that classify 
MBT patients into three classes. Class I patients have a Karnofsky Performance 
Status (KPS) ≥ 70, are younger than 60 years of age, have a well-controlled primary 
tumor and metastatic disease that is limited to the brain [149]. These patients have 
been shown to be the best surgical candidates of the RPA classes. This has demon-
strated that subgroups of this patient population will benefit from more aggressive 
treatment. Various nonograms have been developed in more recent years to help 
define this population of patients more clearly. This has been somewhat of a moving 
target as surgical advancements have been made which can improve outcomes 
through reduced surgical complication and more accurate resection of tumors and 
tumor margins.
3.2 Augmented reality
A number of technological advancements over the last couple of decades have 
culminated to allow for new developments in the realm of augmented reality (AR) 
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use in surgery. Modeling of patient-specific anatomy and pathology has become 
easier to produce and more accurate. With this and other advancements like smaller, 
less bulky AR hardware, intraoperative use of AR more feasible. One of the most 
difficult obstacles AR is facing is determining the best method for image alignment 
and maintaining this alignment during tissue movement [150]. Several studies have 
demonstrated that some of these techniques have an accuracy that meets the clinical 
requirement of under 2 mm [151, 152]. One study even demonstrated an accuracy 
of 0.8 ± 0.25 mm for projecting images on the skull and brain [153]. This can allow 
the surgeon direct visualization of the tumor and has the potential to increase the 
accuracy of resection. It has been demonstrated that AR has shown to be beneficial 
of a 2D approach in rates of correct localization and in efficiency [154]. It has also 
been demonstrated that there may be no difference in terms of error between opera-
tors [155].
AR technology requires much more work before being used routinely in the 
operative setting. Larger scale studies are needed to compare AR in tumor resec-
tion to other techniques like fluorescence guided surgery. These studies need to 
determine whether AR improves clinical outcomes, such as reducing morbidity, 
mortality, and local tumor recurrence. Headset technology and computing platform 
limitations with regard to field of view, positional tracking and coregistration with 
moving tissue need further development. The larger hope for developers is integrat-
ing artificial intelligence, robotics and AR technology to merge machine-learning 
with pre-programmed trajectories and spatial parameters from the overlay [156].
3.3 Whole brain radiotherapy
Whole-brain radiotherapy had long been the standard of care for the manage-
ment of patients with brain metastases (BM). Toxicities associated with whole-brain 
radiotherapy has led to greater selectivity for its use. Multiple Radiation Therapy 
Oncology Group (RTOG, now NRG) have examined optimal WBRT dose regimen 
[157–160]. Typical WBRT fractionation schedule consisted of 20 Gy in five frac-
tions, 30 Gy in 10 fractions, or 37.5 Gy in 15 fractions to produce noticeable effects 
on imaging [161]. Multiple randomized trials have shown WBRT is an effective 
treatment for controlling intracranial metastases and preventing new occurrences 
[162–165]. Studies have also reported that WBRT is associated with both stabilized or 
improvements in neurological signs and symptoms [166–168]. Despite the benefits 
of tumor control and neurological improvements, routine use of WBRT for all 
patients is still controversial. The QUARTZ trial examined patients with nonsmall 
cell lung cancer (NCLC) patients with BM [168]. Over 500 patients were evaluated 
comparing patients receiving WBRT with supportive care. The trial reported no 
difference in survival, quality-adjusted life years, or steroid use. This study suggests 
that WBRT provides little to no benefit for patients unsuitable for surgical resection.
Routine use of WBRT as an adjuvant for patients with BM following resection 
remains controversial [162]. A randomized trial in 1998 examined WBRT after 
surgery and found WBRT was associated with lower rates of recurrence and less 
neurologic death, however, no improvement in overall survival was reported. A 
phase III randomized trial evaluating adjuvant WBRT after surgery versus solely 
stereotactic radiosurgery (SRS) or surgical resection in patients with one to three 
MBTs found greater control by WBRT than the alternatives [164]. In 2016, another 
phase III trial compared postoperative SRS with post-resection WBRT and found 
6-month cognitive deterioration was worse in the WBRT group [169]. Although 
cognitive deterioration was worse following WBRT, intracranial control was still 
better in the WBRT group than the SRS group. No overall survival benefit was 
reported for WBRT and quality of life was worse.
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In an effort to prevent new metastases WBRT has been combined with SRS 
in multiple randomized control trials (RCTs). Despite increased tumor control, 
multiple trials have shown no survival benefit by adding WBRT [163, 164, 170]. 
Furthermore, patients with WBRT following SRS had worse memory, verbal 
fluency and quality of life outcomes [170]. Novel WBRT techniques have been 
developed to preserve neurocognitive and quality-of-life by avoiding the hippo-
campus during treatment. RTOG studied the effect of hippocampal avoidance and 
found much lower declines in Hopkins Verbal Learning Test—Revised compared 
to traditional WBRT [171]. Pharmacologic therapy has provided another method 
for greater neuroprotection after WBRT. Memantine and donepezil have shown 
some potential in reducing the rate of cognitive decline and memory loss in patients 
[172]. Limitations in these studies necessitate more RCTs to validate these protective 
therapies [173].
3.4 Stereotactic radiosurgery
SRS is a treatment for MBTs that converges multiple, well-collimated beams of 
ionizing radiation to tumors, while reducing toxic exposure to surrounding brain 
tissues. In many cases, SRS can be performed as a direct alternative to surgical 
resection. SRS is often preferred over surgical resection for tumor located within or 
near eloquent brain structure for in areas that may be challenging to access such as 
the brainstem, thalamus, and basal ganglia [174, 175]. In addition SRS, may be used 
as an adjuvant following resection. Several retrospective studies and one incomplete 
RCT have compared SRS + WBRT versus resection + WBRT and SRS versus resec-
tion + WBRT. Generally, these studies show no significant difference in outcomes 
between treatment groups for median survival, neurologic death, or functional 
outcome [176–180]. Since survival outcomes are the same for surgical resection and 
SRS, many institutions perform resection in cases with unclear histology, signifi-
cant mass effect or patients with neurological deficits. Radiosurgery is the primary 
option for tumors smaller than 3 cm in diameter. Overall, SRS provides high local 
tumor control rates, low toxicity, and reduced risk of hemorrhage, infection, and 
tumor seeding [181, 182].
More recently, MBC is managed with SRS in combination with targeted agents 
and immunotherapies. SRS and BRAF inhibitors have been safely combined for 
cases of melanoma brain metastases with no resulting toxicity [183, 184]. Several 
studies demonstrated greater median survival for patients treated with SRS and 
targeted therapies in melanoma and nonsmall cell lung cancer brain metastases 
[185–187]. However, some studies have not shown a benefit when combining SRS 
with targeted agents [188, 189]. Concurrent delivery of SRS and immunotherapy 
may enhance the effectiveness of SRS. Several studies have reported better out-
comes after treating metastatic brain melanoma with combination radiosurgery and 
immunotherapy [221, 222]. One downside to this treatment is the inflammatory 
response may be overactive resulting in elevated peritumoral edema and more 
severe neurologic symptoms [190, 191]. Efficacy and safety of concurrent SRS and 
immunotherapy needs further investigation.
3.5 Chemotherapy
Cytotoxic chemotherapy for metastatic brain cancer is currently considered 
when surgical resection and radiation therapies are not adequate or sufficient for 
treatment. This is often the case for patients with lower prognostic factors such as 
patients in RPS class II or III. Patient who have no targetable genetic factors and 
for which immunotherapeutic agents are inappropriate or contraindicated are 
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considered for cytotoxic chemotherapeutic agents. The agent(s) change based on 
the primary tumor. A number of phase II and III trials have evaluated the role of 
chemotherapy for NSCLC MBTs. Patients were treated with six cycles of cisplatin 
and pemetrexed followed by WBRT in one trial and recorded a response rate of 
34.9% [192]. Median survival in the same study was 7.4 months. A more recent cis-
platin/pemetrexed study examined patients with BM from lung adenocarcinoma. 
Overall response rates were comparable to the aforementioned study with median 
overall survival of 12 months [193].
A randomized phase III trial reversed the order of treatment in patients with 
NSCLC MBTs where WBRT was followed by chemotherapy [194]. In this study, 
patients received cisplatin and vinorelbine for six cycles. Intracranial response rates 
were similar for both the group receiving chemotherapy alone and those receiv-
ing WBRT early and concurrently [194]. Another study evaluated paclitaxel and 
cisplatin chemotherapy in MBTs from NSCLC. The response rate after completion 
of the course resulted in slightly higher response rates (38%) compared to previ-
ous trials. Multiple chemotherapeutic agents have been studied for the treatment 
of MBTs from breast cancer. Cisplatin, etoposide, cyclophosphamide, high dose 
methotrexate and 5-fluorouracil have achieved response rates over 50% [195, 196]. 
Innovation to systemic chemotherapy for brain metastases has been modest with 
regard to drug development. Modifications to drug delivery ranging from direct 
injection, convection-enhanced, and implantable seeds have been examined for 
efficacy [197–200].
3.6 Brachytherapy
Brachytherapy delivers high doses of radiation with small pieces of radioac-
tive material placed within the resection cavity for treating residual tumor. 
Brachytherapy enables delivery of customizable doses for sparing of functional 
tissue. Brachytherapy seeds have been used in neurosurgery for over a half-century 
with mixed results [201–203]. Isotypes used in brachytherapy changed since the 
1960s. More recently, cesium-131 and iodine-125 are now replacing gold and 
iridium-based isotypes. Modern brachytherapy has been studied for the treatment 
of meningiomas, gliomas, and metastases [204, 205]. Intraoperative brachytherapy 
may also be used as salvage treatment for recurrent cancers [206]. Recently, a 
randomized trial evaluated cesium-131 for the treatment of MBTs [207]. Twenty-
four patients underwent total resection followed by intraoperative placement of 
cesium-131 with a planned dose of 80 Gy [207, 208]. The patients had no local 
recurrence, symptomatic radiation necrosis, and minimal surgical morbidity. 
Despite limitations in the study including small sample size, these promising results 
confirm the need for more robust trials.
3.7 Laser interstitial thermal therapy
MR-guided laser interstitial thermal therapy (LITT) builds upon previ-
ous thermal ablation technology with safer and more accurate results. LITT 
is performed by implanting a laser catheter into the tumor and heating it to 
temperatures monitored by MRI thermography. Patients often return home the 
day after treatment. Two studies have shown promising results for tumors fail-
ing to respond to radiotherapy. LITT is minimally invasive and requires only a 
2-mm access port. Four patients with six tumors were treated with LITT without 
complications and no recurrence within 90-day follow up [209]. Another study 
demonstrated similar results using LITT for five metastases [210]. More recent 
studies have bolstered LITT in larger sample sizes as an alternative option for 
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patients unresponsive to radiotherapy. Ahluwalia et al. reported LITT stabilized 
the Karnofsky Performance Scale (KPS) score, prolonged quality of life, reduced 
steroid usage with minimal complications [211]. With the advent of real-time 
monitoring and damage estimation, LITT has emerged as a valuable management 
modality for metastatic tumors. Larger scale trials need to standardize protocols 
and specify indications [212].
3.8 Checkpoint inhibitors
Immunotherapies are treatments that activate the immune system to destroy 
cancer and have been around for over a century. The brain has limited infiltration 
of leukocytes [213]. Following an injury or metastasis, infiltration of non-resident 
cell will take place. Metastatic brain infiltrate consists of a mixed array of immune 
cells, specifically, CD3+, CD4+, CD8+, FoxP3+, CD45RO+ lymphocytes, natural 
killer (NK) cells, and macrophages [214, 215]. Patient survival is correlated to the 
quantity of tumor-infiltrating leukocytes in peritumoral edema [214]. In the last 
decade, exciting advancements from a group of monoclonal antibody treatments 
called checkpoint inhibitors. Checkpoint inhibitors act to prevent lymphocyte sup-
pression. Several clinical trials have studied immune checkpoint inhibitors efficacy 
on patients with MBC [216–218].
Programmed cell death proteins (PD-1) are immunomodulatory molecules 
expressed on the surfaces of immune cells to prevent T-cell overactivation [219]. 
There are two ligands for PD-1 (PD-L1 and PD-L2) found on the surface of tis-
sue macrophages that regulate the immune response of T cells against pathogens 
and foreign cells [220]. Cancers are known to express PD-L1 and PD-L2 on their 
surface to suppress the cytotoxic T lymphocytes (CTLs) response. Nivolumab and 
pembrolizumab are both anti-PD-1 antibodies that selectively block PD-1 receptor 
interaction with ligands PD-L1 and PD-L2. These antibodies were approved by the 
FDA based on efficacy data from phase III trials for the treatment of melanoma, 
NSCLC, renal cell carcinoma, and head-neck cancer [221–228]. Three new PD-1 
antibodies against PD-L1 (durvalumab, atezolizumab, and avelumab) are currently 
being investigated in phase III trials. Despite a large number of studies examining. 
Caponnetto et al. provide a timely overview of immunotherapy studies for the 
treatment of brain metastases [229]. PD-L1 antibodies have been studied on NSCLC 
brain metastases that resulted in the majority of participants discontinuing treat-
ment from exacerbation of neurologic symptoms [230]. A study by Goldman et al., 
did not report high toxicity rates in the treatment of NSCLC BM with nivolumab 
and observed improved overall survival for patients [231]. Large prospective studies 
will be needed to confirm initial results.
Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is another simi-
lar checkpoint molecule regulating CTL activity. CTLA-4 is on the surface of 
CTLs, which connect with CD28 and deactivate T cells [232]. Ipilimumab, an 
anti-CTLA-4 antibody, has demonstrated promising results in multiple trials in 
patients with metastatic melanoma [233, 234]. Another Phase III trial reported 
enhanced overall survival in patients with advanced melanoma and BM [233]. 
More tests will be required to determine if ipilimumab provides durable responses 
against melanoma, which is a limitation for BRAF inhibitors. Combination 
ipilimumab and nivolumab has shown promising results in several studies [228, 
235, 236]. Unfortunately, there are no studies testing combination therapy on 
non-melanoma tumor types. Combination immunotherapy with radiotherapy is 
limited MBT studies, but radiation necrosis is an emerging concern [237]. Long-
term effects of combination treatment and more robust studies to determine its 
efficacy.
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3.9 Adoptive cellular therapy
Adoptive Cellular Therapy (ACT) for the treatment of BM extracts T cells 
from the patient, genetically modify and culture the cells in vitro before return-
ing them to the same patient. Growth factors are usually added to the cells prior 
to reintroduction to stimulate survival and expansion in vivo [238]. There are 
three forms of ACT that use T cells including tumor-infiltrating lymphocyte (TIL) 
therapy, chimeric antigen receptor (CAR) T-cell therapy, and endogenous T-cell 
(ETC) therapy. Similar to the process described previously, TIL therapy removes 
T cell from the patient’s tumor, expands them in vitro with an immune signaling 
molecule (Interleukin-2), before being infused back into the patient [239]. CAR 
T-cell therapy genetically engineer T cells to recognize specific tumor antigens. 
ETC neither requires a tumor source nor genetic engineering. Rather, ETC selects 
intrinsically tumor-reactive T cells in the peripheral blood and expands them. These 
cells are exceptionally rare and require intense processing methods. Several studies 
have reported successful treatment of melanoma brain metastases with ACT or 
combination therapy that includes ACT [240–243].
3.10 Targeted cancer therapy
Targeted cancer treatments are treatments that target specific proteins, pro-
cesses, and pathways that have become pathological in cancer cells. Generally, 
targeted entities involve surface proteins on cancer cell membranes, faulty or 
overactive enzymes in cytoplasm, or faulty cell signaling pathway. The majority of 
these therapies can be classified under two categories, namely, monoclonal antibod-
ies or kinase inhibitors. It is estimated that 18% of patients with MBTs are suscep-
tible to targeted therapies [244]. Recent developments in the field of tumor biology 
have presented new therapeutic targets with greater BBB penetrance for a variety of 
metastatic brain cancers.
3.11 Breast cancer and brain metastases
MBTs occur in 10–15% of patients with breast cancer, although studies based 
on findings at autopsy suggest that the incidence is closer to 40% of cases [245]. 
Human epidermal growth factor receptor-2 (HER2) is overexpressed in approxi-
mately 15–20% of patients with breast cancer [246]. HER2-positive breast cancer is 
associated with higher rates of MBTs and prolonged survival than HER2-negative 
breast cancer [246]. Trastuzumab, a recombinant monoclonal antibody against 
HER2, improves tumor control and confers a survival benefit for HER2-positive 
patients [246]. However, the relative higher incidence of BM when treated with 
trastuzumab has prompted development of alternative therapies with enhanced 
blood-brain barrier (BBB) penetrance [247]. Lapatinib, a dual tyrosine kinase 
inhibitor (TKI) of epidermal growth factor receptor (EGFR) and HER2, has been 
used for treating patients with resistance to trastuzumab [248]. In contrast to 
trastuzumab, lapatinib can penetrate the BBB when combined with capecitabine. 
The intracranial response rate was 66% in a Phase II study of HER2-positive breast 
cancer patients with brain metastases [249–251]. By comparison, lapatinib as a 
single agent demonstrates only modest activity [249, 252]. Similar findings were 
observed with neratinib in combination with capecitabine [253, 254].
Triple-negative breast cancer (TNBC) does not express hormone receptors and 
presents a greater challenge identifying molecular targets. Approximately, 10–15% of 
breast cancers are TNBC, which have higher incidence and reduced survival [245, 255]. 
One potential target is poly adenosine diphosphate ribose polymerase (PARP) inhibitors 
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that potentiate chemotherapy and radiotherapy [256]. PARP inhibitors can be effective 
as single agents for BRCA associated breast and ovarian cancers. Iniparib has begun 
Phase II trials and in combination with irinotecan yielded a modest benefit for treatment 
of TNBC [257]. Another potential candidate for TNBC are histone deacetylase (HDAC) 
inhibitors that prevent transcription of particular genes and expression of cellular 
activities [258, 259]. Vorinostat, an HDAC inhibitor, has prevented brain metastatic 
colonization by over 62% in mouse models [260]. Polo-like kinase 1 (Plk1) is another 
well-performing molecular target in BM from breast cancer. Inhibitors of Plk1 prevented 
the development of large BMs by 62% and prolonged survival by 17% in mouse models 
with breast cancer [261]. Plk1 inhibitors may be a new target for MBT prevention and 
treatment [262].
However, studies reported to date have not demonstrated improvements to 
overall survival with these treatments. An important factor for these findings 
may be the failure of targeted therapies to achieve complete responses in the brain 
[263]. To address these shortcomings, researchers are unraveling the mechanisms 
for therapeutic resistance, revising brain metastasis models, and developing more 
penetrative treatments. Specifically, these modifications include patient-derived 
xenografts, 3D bioprinted metastatic models, genetically-modified mouse models, 
and nanoparticles for enhanced drug delivery [264]. Vorinostat has undergone a 
Phase I clinical trial to study its use as a radiosensitizer for WBRT [265]. Treatment 
was well-tolerated by patients and is expected to enter a Phase II study.
3.12 Lung cancer and brain metastases
Approximately 40–50% of patients with lung cancer are diagnosed with MBC 
during their disease course [266]. Small cell lung cancer (SCLC) has a greater 
tendency to metastasize early in its development [267]. MBTs are more commonly 
encountered in this histological type than NSCLC. Overall, lung cancer patients 
commonly present with brain metastases at diagnosis [268]. As of today, no tar-
geted therapies have been developed for BM in SCLC.
Roughly, 2–4% of lung cancer brain metastases originate from EGFR mutant 
[269]. Another 5% of lung cancer MBTs derive from ALK-translocated primary 
tumors (ibid). Gefitinib and Erlotinib are two first-generation EGFR TKIs approved 
for the management of EGFR mutant NSCLC [270]. Recent evidence has validated 
its effectiveness in decreasing the tumor burden by over 30% in over 80% of 
patients [271, 272]. The median time to progression was also extended for patients 
treated with erlotinib from 11.7 to 5.8 months [271]. Other studies have confirmed 
these findings with overall progression-free survival (PFS) of 15.2 months versus 
4.4 months for patients without the mutation [273]. Gefitinib or erlotinib may be 
useful as prophylaxis since they were found to reduce the risk of progression in 
patients with NSCLC [274]. Similar findings have been observed for another EGFR 
inhibitor, osimertinib [275]. Osimertinib outperformed patients receiving chemo-
therapy in a Phase III trial with brain metastasis patients (ibid). Crizotinib is the 
first TKI approved for ALK-translocated lung cancer [276]. However, it exhibited 
suboptimal BBB penetration. Next-generation TKIs (e.g., brigatinib and alectinib) 
targeting translocated ALK have greater penetrance with greater intracranial 
responsiveness [277, 278].
3.13 Melanoma and brain metastases
Melanoma brain metastases have also benefited from targeted therapies. MBTs 
are found approximately in 10–20% of patients with melanoma, although autopsies 
suggest the incidence is as high as 70% in such patients [279]. Targeted therapies 
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such as BRAF V600 TKI dabrafenib have exhibited 39% intracranial response in 
BMs that increased to 58% in studies combining dabrafenib and trametinib [280, 
281]. Another BRAF inhibitor, vemurafenib, recorded a response rate of 18% in 
another trial [282]. In a previous study, vemurafenib resulted in complete or partial 
tumor regression and improved overall survival in patients positive for BRAF 
V600E metastatic melanoma [283]. The downside with BRAF inhibitors is that the 
majority of melanoma patients develop drug resistance and eventual relapse [284]. 
Combination therapies with targeted approaches will be necessary to counteract 
cancer resistance.
4. Experimental therapies
4.1 Nanooncology
Biotechnologies are increasingly used in cancer research [285]. The application 
of nanotechnology in cancer research is termed nanooncology and has generated 
promising solutions to address our current limitations in imaging and treatment of 
brain tumors [286]. Currently, two nanotechnology-based products are approved 
for the treatment of cancer, e.g., Doxil (liposomal doxorubicin) and Abraxane 
(nanoparticle formulated paclitaxel). Novel cancer therapeutics ranging from tiny 
carbon nanotubes and polymeric nanoparticles to large-scale thermal therapies 
such as magnetic nanoparticle-based hyperthermia [287, 288]. This field of research 
is growing rapidly with approximately 150 drugs currently in development that 
incorporate nanotechnology. The purpose of this section is to provide exposure to 
the field of nanooncology and highlight some promising materials.
4.2 Liposome-based nanoparticles
Liposomes are one of the most established nanomedicines in cancer therapy 
and theranostics. It is an effective delivery system with their flexibility, versatility, 
biocompatibility, and biodegradability [289]. Liposomes resemble biological mem-
branes by adopting a lipid bilayer structure and house a wide range of cytotoxic 
drugs and imaging agents. The vesicle structure of liposomes permits encasement 
of a variety of lipophilic and hydrophilic cargos. The drug adopts the pharmacoki-
netic properties of the liposomal carrier until they are released [290]. This feature 
results in enhanced therapeutic index and reduction in systemic toxicity [291–293]. 
Additionally, hydrophilic polymers and ligands may be attached to the liposomes to 
modulate circulation time and targeting capabilities [294, 295]. Several studies have 
reported enhanced uptake and efficacy of ligand-targeted liposomes in diseased 
tissue versus non-targeted liposomes. Ligands are selected that have high affinity 
for highly-expressed receptor on cancer cells [296, 297].
Different strategies have been developed to promote the loading and release 
of therapeutics for cancer treatments. Liposomes act to protect encapsulated 
drugs from degradation, dilution and premature release [298]. As a consequence, 
therapeutic efficacy of anticancer drugs are increased since higher amounts reach 
the destination [299, 300]. Liposomal doxorubicin-cyclophosphamide for the 
treatment of breast cancer patients with MBTs demonstrated greater response rates 
and median survival time for both mouse models and human patients [299, 300]. 
One challenge for liposome-based nanoparticles is the encapsulation inefficiency 
(<30%) for passive loading of hydrophilic therapeutics [301]. In contrast, hydro-
phobic drugs tend to load with much higher efficiency because they readily dissolve 
inside the lipid bilayer.
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4.3 Quantum dots
Quantum dots (QDs) are extremely small nanoparticles measuring a few 
nanometers in size. QDs emit light of specific frequencies modifiable by altering the 
size, shape, and material of the dots. QDs possess great potential for tumor fluores-
cence imaging and delivering therapies. Fluorescence imaging is a potent tool for 
cancer diagnosis and achieves more complete resections [302]. Biomolecules can 
be used to modify QDs which provides several improvements from other organic 
fluorophores, e.g., higher photoluminescence efficiency, greater photostability, and 
sharp emission profile. QD-based fluorescence also has good biocompatibility and 
low toxicity [303–307].
Visible fluorescence imaging uses light in the visible wavelength spectrum 
(400–700 nm) and is adept at cancer diagnosis and enhancing spatial resolution. 
For in vivo tumor fluorescence imaging, imaging agent delivery to brain tumors is 
challenging because the BBB restricts the passage of large molecules [308]. Thus, 
BBB prevents the transposition of many imaging agents and cancer therapeutics 
ergo attenuating their effect on tumor treatment and illumination. QDs provide a 
workaround for these physiological constraints due to their miniscule dimensions. 
Recent studies have developed QD nanoprobes that cross the BBB and target tumors 
specifically [309, 310]. These QDs cross the BBB and target cancer cells for in vivo 
imaging.
4.4 Gene therapy
Gene therapy of the nervous system is now a commonplace tool used around 
the world. Widely used to generate preclinical models, gene therapy is now dem-
onstrating success in the clinic for both safety and efficacy for the treatment of 
congenital blindness and neurodegenerative disorders [311, 312]. A major compo-
nent to gene therapeutics is the delivery system known as vectors. Vectors are com-
monly categorized as viral and non-viral vectors. Adenoviral vectors have proven 
valuable in the development of anticancer agents by selectively replicating within 
cancer cells [313]. Retroviral vectors are another useful delivery system for cancer 
treatment. Previous studies have demonstrated its ability to activate enzymes that 
convert 5-fluorocytosine (5FC) into toxic 5-fluorouracil (5FU) for treatment of 
gliomas [314, 315]. RRV with prodrug is currently being tested in randomized 
trials, however, this concept may be tested on MBTs in combination with immu-
notherapy [316]. Another rising technology is Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR) that allows gene editing within organisms. 
Recently, CRISPR was used to engineer tumor cells to exhibit homing behavior 
[317]. After engineering, cells are released back into circulation and return back 
to the main tumor site. Cells were designed to secrete death receptor-targeting 
ligands that destroy the main tumor cells. Self-homing cells were also programmed 
with a drug-triggered cellular suicide system to eliminate them following tumor 
death. CRISPR has also been used to enhance therapeutic T cells in cancer immu-
notherapy [318]. These new capacities may expand into brain metastatic treatment 
in the near future.
5. Conclusion
In 1971, the National Cancer Act was signed to strengthen the National Care 
Institute with the objective to eliminate cancer as a leading cause of death in the 
United States [319]. This was expected to be achieved by funding research for 
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understanding the mechanisms of cancer biology and developing effective treat-
ments. Although cancer death rates have declined for the past 25 years in the United 
States, the results have overall been disappointing when considering total cancer 
deaths and mortality rate. Much of the progress against cancer can be attributed 
to the decline in tobacco use and the development of screening tools for earlier 
detection [320]. Since 1971, there has been expansion of knowledge in cancer 
biology and diversification of diagnostic tools and treatment options. With respect 
to brain metastases, the median survival has improved modestly [321] and innova-
tive approaches to MBC management continue to emerge in the fields of imaging, 
biotechnology, and pharmaceuticals. Having said that, it is fair to question whether 
the rate of progress for cancer patient outcomes and innovation is decelerating and 
whether subsequent inventions will be as impactful as those previous [322, 323]. 
As Gordon has pointed out, successive Industrial Revolutions after the 1960s have 
made depreciating impacts on productivity and economic growth [322]. A similar 
trend is observed in pharmaceuticals with a noticeable decline in research and 
development (R&D) efficiency defined as the number of new drugs approved for 
every billion dollars spent on R&D [323]. Studies have haggled over the cost for one 
new drug approval with estimates between roughly $700 million and $2.5 billion 
dollars [324, 325]. This trend is referred to as Eroom’s Law, which means drug 
discovery becomes slower and more expensive with time. Additionally, we have 
seen a decline in the state of competition and economic dynamism characterized 
by rising mergers and declining start-up rates [323, 326]. Even with newer treat-
ments reaching market, we see evidence of diminishing returns for the treatment of 
cancer [327]. Despite these problematic economic and healthcare patterns, innova-
tion in MBC management remains resilient producing robust tools for improving 
treatment safety and efficacy.
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